Does P Gp Or Bcrp Substrates Interact with Mavorixafor?
P Gp Or Bcrp Substrates and Mavorixafor have a moderate drug interaction according to U.S. FDA drug labeling data. Increase mavorixafor Cmax and AUC. Monitor for adverse reactions and reduce dosage by 100 mg steps if necessary, but not below 200 mg. The mechanism involves inhibition of p-glycoprotein-mediated efflux of mavorixafor. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Moderate
- Mavorixafor Class
- CXC Chemokine Receptor 4 Antagonist
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
How This Interaction Works
The interaction between P Gp Or Bcrp Substrates and Mavorixafor occurs because inhibition of p-glycoprotein-mediated efflux of mavorixafor. Clinically, this means increase mavorixafor cmax and auc. monitor for adverse reactions and reduce dosage by 100 mg steps if necessary, but not below 200 mg. This is classified as a moderate interaction. While it may not require stopping either medication, your healthcare provider should be aware you are taking both so they can monitor for potential effects and adjust treatment if necessary.
What To Tell Your Doctor or Pharmacist
If you are taking P Gp Or Bcrp Substrates and your doctor is considering prescribing Mavorixafor (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider